

Forum on Neuroscience and Nervous System Disorders
Forum on Drug Discovery, Development, and Translation
Roundtable on Genomics and Precision Health

Precision Medicine in Neuroscience: Tools, Translation, and Implementation: A Workshop

March 4, 2026 | 2:00pm–5:00pm ET

March 5, 2026 | 9:00am–4:00pm ET

<https://www.nationalacademies.org/projects/CHPP-BHS-25-02/event/46261>

ATTENDEE PACKET



Table of Contents

AGENDA.....	3
Workshop Agenda	4
WORKSHOP INFORMATION.....	11
Planning Committee Roster and Biographies.....	12
Speaker Biographies	17
Preventing Discrimination, Harassment, and Bullying: Policy	29
FORUM/ROUNDTABLE INFORMATION.....	30
Neuroscience Forum Overview	31
Drug Forum Overview	34
Genomics Roundtable Overview	36

AGENDA

Precision Medicine in Neuroscience: Tools, Translation, and Implementation: A Workshop

Wednesday, March 4, 2026: 2:00 pm – 5:00 pm ET

Thursday, March 5, 2026: 9:00 am – 4:00 pm ET

Objectives

- Highlight case examples where precision medicine approaches have informed research, diagnosis, treatment, and disease/disorder reclassification in neuroscience.
- Examine emerging tools and technologies—including biomarkers, multi-omics, computational psychiatry, and artificial intelligence—and their applications across neuroscience research and clinical care.
- Consider barriers and opportunities for implementation, including provider education, patient engagement, payer and regulatory models, data privacy, clinical integration, and potential risks.
- Explore cross-disease/disorder and holistic frameworks, including how precision medicine approaches can address comorbidities and support a broader brain health model.

Program At-A-Glance

- **Day 1**
 - Welcome & Introductory Remarks
 - Workshop Overview
 - Keynote Presentations
 - Session 1:** Precision Biology for Discovery and Defining Disease/Disorder
 - Session 2:** Precision Frameworks for Patient Identification and Stratification
- **Day 2**
 - Welcome & Day 1 Recap
 - Keynote Presentations
 - Session 3:** Precision Measures to Monitor Disease/Disorder and Treatment
 - Session 4:** Precision Strategies for Effective Clinical Trial Design
 - Lunch
 - Session 5:** Precision Systems to Deliver Care at Scale
 - Session 6:** Driving Ecosystem Investment in Scalable Precision Medicine Infrastructure for Brain Health
 - Session 7:** Synthesis and Opportunities for Precision Medicine in Neuroscience

WEDNESDAY, MARCH 4, 2026

2:00pm **Introductory Remarks**

Frances Jensen, University of Pennsylvania, *Forum on Neuroscience and Nervous System Disorders Co-chair*

Deanna Barch, Washington University in St. Louis, *Forum on Neuroscience and Nervous System Disorders Co-chair*

2:05pm **Workshop Overview**

Rosa Canet-Avilés, California Institute for Regenerative Medicine, *Workshop Co-chair*

Gayle Wittenberg, Johnson & Johnson, *Workshop Co-chair*

2:10pm **Keynote Presentations**

Steve Hyman, Broad Institute of MIT and Harvard, *Planning Committee Member*

Jamie Heywood, Alden Scientific, PatientsLikeMe, ALS Therapy Development Institute, AOBiome Therapeutics

2:40pm **Session 1: Precision Biology for Discovery and Defining Disease/Disorder**

Objectives: This session will examine how emerging tools and technologies—including biomarkers, multi-omics, and artificial intelligence—contribute to a deeper understanding of human neurobiology in health and disease/disorder. Talks will explore the strengths and limits of these technologies in tackling the complexity of the human brain—and the challenges in distinguishing causal insight from correlation. A central theme is at what point is our biological understanding strong enough to justify moving forward?

Key discussion questions:

- What kinds of biological evidence actually shape decisions?
- When does correlation become actionable insight?
- What data are we collecting today that meaningfully shift disease/disorder definitions toward precision, and what data are we collecting that do not?

2:40pm **Session Overview**

Julie Harris, Allen Institute, *Planning Committee Member*

Dimitri Krainc, Northwestern University, *Planning Committee Member*

2:45pm **Speaker Presentations**

Daniel Geschwind (virtual), University of California, Los Angeles

Mariano Gabitto, Allen Institute

Rhoda Au, Boston University

3:20pm **Moderated Panel and Audience Q&A**

3:45pm **BREAK**

3:55pm Session 2: Precision Frameworks for Patient Identification and Stratification

Objectives: Positioned between discovery and development, this session explores how precision biology data are assembled into biomarker-driven and composite frameworks for patient stratification across neurological and psychiatric disorders, including threshold selection and uncertainty management, and how these choices impact regulatory relevance and downstream clinical trial design. Speakers will highlight contrasts in progress in Alzheimer's disease and Parkinson's disease vs psychiatric disorders, where stratification remains challenging.

Key discussion questions:

- Should precision frameworks be biology-first or phenotype-first and are we ready to revise diagnostic categories accordingly?
- How much uncertainty and misclassification is acceptable to ensure a framework is still usable?
- How can frameworks evolve with new biological understanding without losing regulatory confidence?

3:55pm **Session Overview**

Laura Bustamante, Washington University in St. Louis, *Planning Committee Member*
Brian Fiske, Michael J. Fox Foundation for Parkinson's Research, *Planning Committee Member*

4:00pm **Speaker Presentations**

Kathleen Poston (*virtual*), Stanford University
Frederike H. Petzschner, Brown University
Diane Stephenson, Critical Path Institute

4:35pm **Moderated Panel and Audience Q&A**

4:55pm **Day 1 Concluding Remarks**

Rosa Canet-Avilés, California Institute for Regenerative Medicine, *Workshop Co-chair*
Gayle Wittenberg, Johnson & Johnson, *Workshop Co-chair*

5:00pm **Adjourn Day 1**

THURSDAY, MARCH 5, 2026

9:00am **Review of Day 1 and Preview of Day 2**

Rosa Canet-Avilés, California Institute for Regenerative Medicine, *Workshop Co-chair*

Gayle Wittenberg, Johnson & Johnson, *Workshop Co-chair*

9:05am **Keynote Presentations**

Husseini Manji (*virtual*), UK Govt Mental Health Goals Program, Oxford University,
Yale University, Duke University

Michelle Colder Carras, Carras Colder Carras LLC

9:35am **Session 3: Precision Measures to Monitor Disease/Disorder and Treatment**

Objectives: This session focuses on prognostic and longitudinal assessment, an area of particular challenge in brain disorders. Topics include predicting and assessing disease/disorder progression using imaging, biofluid, genetic, and digital markers along with clinical data. Discussion will highlight feasibility, heterogeneity and interpretability across conditions, and how these factors can influence clinical management and therapeutics.

Key discussion questions:

- How can biomarker, clinical, and other data be integrated for prognosis and prediction of progression?
- What do biomarker changes over time tell us about the biology of disease/disorder?
- How can initial and longitudinal biomarker profiles inform therapeutic interventions, including initiation, dose changes, discontinuation, or switching?

9:35am **Session Overview**

Linda Brady, National Institute of Mental Health, *Planning Committee Member*

9:40am **Speaker Presentations**

Reisa Sperling, Harvard Medical School

Kenneth Marek, Institute of Neurodegenerative Disorders

Scott Woods, Yale University

10:15am **Moderated Panel and Audience Q&A**

10:45am **BREAK**

11:00am Session 4: Precision Strategies for Effective Clinical Trial Design

Objectives: This session will explore how biological insight informs drug development and therapeutic strategy. Discussion would address patient stratification and enrichment approaches, trial design, endpoint choice, and biomarker translational medicine strategy. The emphasis is on how precision approaches influence decisions about which intervention is appropriate for which patient, and under what evidentiary conditions.

- Given a biological hypothesis, what intervention do we choose for which patient population?
- How is precision medicine incorporated across the clinical development stages
- How do we ensure generalizability of biomarker results from studies?

11:00am Session Overview

Michael Irizarry, Eisai, *Planning Committee Member*

11:05am Speaker Presentations

Toby Ferguson, Alnylam Therapeutics

Hugh Marston, Boehringer Ingelheim

Larisa Reyderman, Eisai

Valentina Mantua, Food and Drug Administration

11:50am Moderated Panel and Audience Q&A

12:20pm LUNCH

1:00pm Session 5: Precision Systems to Deliver Care at Scale

Objectives: This session examines what happens when precision medicine approaches move from trials and centers of excellence into routine clinical care. Discussion will focus on the practical constraints that shape real-world delivery (clinical workflows, workforce capacity, infrastructure, reimbursement, ethical obligations, and health-system readiness) and how these factors determine whether precision approaches can be scaled, sustained, and deliver value to patients and health systems.

Key discussion questions:

- What breaks when precision medicine moves into real-world practice?
- How can implementation barriers be overcome?
- How do health systems decide what is worth adopting and sustaining?
- Where do ethical, economic, and clinical considerations collide?
- Why do some precision approaches stall despite strong biology?

1:00pm

Session Overview

Bruce Korf (*virtual*), University of Alabama, Birmingham, *Planning Committee Member*

1:05pm

Speaker Presentations

Nilufer Ertekin-Taner (*virtual*), Mayo Clinic, Florida
Soeren Mattke (*virtual*), University of Southern California
Nita Limdi, (*virtual*) University of Alabama at Birmingham

1:40pm

Moderated Panel and Audience Q&A

2:05pm

BREAK

2:15pm

Session 6: Driving Ecosystem Investment in Scalable Precision Medicine Infrastructure for Brain Health

Objectives: This session will explore perspectives on the precision medicine infrastructure needed to advance brain care, including shared platforms that support translation, reduce risk, and improve patient outcomes. The discussion will examine structural scientific, regulatory, financial, and governance challenges that limit scale, interoperability, and long-term sustainability and cannot be addressed by individual institutions alone. Participants will also consider public–private partnership and investment approaches and what factors may inform future action-oriented efforts to move precision medicine tools from research assets toward broader clinical and public health impact over the next several years.

Key Discussion Questions:

- What shared platforms (e.g., biomarkers, biorepositories, brain banks, AI and real-world data systems) are most critical to accelerate translation, de-risk innovation, and improve patient outcomes, and what cross-cutting scientific, regulatory, financial, and governance constraints limit their interoperability, adoption, scalability, and long-term sustainability—particularly those that cannot be addressed by individual institutions or stakeholders alone?
- What lessons can be drawn from existing partnership and investment models (e.g., ARPA-H, IHI, industry consortia) to mobilize coordinated national investment and leverage international collaboration, share risk, and ensure tools are built as durable, accessible infrastructure rather than fragmented pilots?
- What elements would be important to include in an actionable roadmap that outlines priority investments, partnership structures, key institutions, and policy levers required over the next 3–5 years to scale precision medicine tools from research assets into routine clinical and public health impact?

- 2:15pm** **Session Overview**
Magali Haas, Cohen Veterans Bioscience, Psilera, *Planning Committee Member*
Elisabetta Vaudano (virtual), Innovative Health Initiative
- 2:20pm** **Speaker Presentations**
Martien Kas (virtual), University of Groningen
Tristan Glatard, Centre for Addiction and Mental Health
Julian Tillmann, Roche
Nathaniel Mohatt, Advanced Research Projects Agency for Health
- 3:00pm** **Moderated Panel and Audience Q&A**
- 3:25pm** **Session 7: Synthesis and Opportunities for Precision Medicine in Neuroscience**
Objectives: Examine the core themes that have been highlighted during the workshop.
Consider next steps to advance precision medicine research and care for brain disorders.
- 3:25pm** **Session Overview**
Rosa Canet-Avilés, California Institute for Regenerative Medicine, *Workshop Co-chair*
Gayle Wittenberg, Johnson & Johnson, *Workshop Co-chair*
- 3:30pm** **Themes & Future Opportunities Discussion**
Session Moderators
- 3:55pm** **Concluding Remarks**
Rosa Canet-Avilés, California Institute for Regenerative Medicine, *Workshop Co-chair*
Gayle Wittenberg, Johnson & Johnson, *Workshop Co-chair*
- 4:00pm** **Adjourn Day 2**

WORKSHOP INFORMATION

Planning Committee Biographies



Rosa Canet-Aviles, Ph.D. (*Co-chair*) is the Chief Scientific Officer at the California Institute for Regenerative Medicine (CIRM), where she leads the agency's scientific strategy and program portfolio to accelerate the development and delivery of transformative cell and gene therapies. She oversees CIRM's investments across discovery, preclinical, and clinical research, as well as its infrastructure and education programs, ensuring alignment with California's mission to bring treatments to patients in need.

As CSO, Rosa drives the implementation of CIRM's strategy integrating science, clinical development, and patient access to maximize impact. She is spearheading initiatives to build technology platforms, expand clinical trial networks, and strengthen equitable access pathways, positioning California as a global leader in regenerative medicine.

Rosa brings nearly two decades of experience leading multi-stakeholder initiatives across biopharma, government, and nonprofit sectors. Before rejoining CIRM, she served as Director of Strategic Alliances at Eisai's Center for Genetics Guided Dementia Discovery (G2D2), where she shaped external innovation partnerships and alliance strategy. Prior to Eisai, Rosa directed the Neuroscience Research Partnerships at the Foundation for the NIH, where she led landmark public-private initiatives such as the Accelerating Medicines Partnership (AMP) for Alzheimer's, Parkinson's, and Schizophrenia, and the Alzheimer's Disease Neuroimaging Initiative (ADNI3), working closely with NIH, FDA, academia, and industry.

Rosa holds a Ph.D. in neuroscience from the University of Leeds School of Medicine, UK, and a B.S. in organic chemistry from the Central University of Barcelona.



Gayle Wittenberg, Ph.D. (*Co-chair*) is Vice President of Precision Measures, Neuroscience Research & Development at Johnson & Johnson Innovative Medicine, where she provides strategic and operational leadership for measurement, biomarkers, and data-driven decision-making across the neuroscience pipeline. Previously, she served as Vice President Neuroscience Data Science & Digital Health at Janssen R&D, where she built and led a multidisciplinary organization spanning molecular & discovery, digital, clinical biomarkers and real-world evidence. Dr. Wittenberg's expertise lies at the intersection of neuroscience, data science and precision medicine, with a particular focus on how quantitative measurement, computational models and digital and biological markers can enable actionable clinical decisions. Her work has emphasized translating emerging tools into scalable, decision-grade approaches for neurological and psychiatric disorders, while addressing practical challenges related to validation, workflow and adoption. She has received multiple leadership and innovation awards in industry and has served on scientific review panels and advisory committees spanning neuroscience, data science and translational research. Dr. Wittenberg earned her PhD in molecular biology and neuroscience from Princeton University following undergraduate training in physics and engineering at Oregon State University.



Linda Brady, Ph.D. serves as the Director of the Division of Neuroscience and Basic Behavioral Science at the National Institute of Mental Health (NIMH). In this role, she provides scientific, programmatic, and administrative leadership for an extramural research program portfolio in basic neuroscience to support NIMH's mission of transforming the understanding and treatment of mental illnesses. Dr. Brady has directed programs in neuropharmacology, drug discovery, and clinical therapeutics and organized Consortia focused on ways to accelerate the development and clinical application of radiotracers in clinical research. She has provided leadership for the National Cooperative Drug/Device Discovery/Development Groups for the Treatment of Mental Disorders and First in Human and Early-Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders initiatives. Dr. Brady serves as co-chair of the Neuroscience Steering Committee of the Biomarkers Consortium, a public-private research partnership of the Foundation for the National Institutes of Health (FNIH) that focuses on discovery, development, and qualification of biological markers to support drug development, preventive medicine, and medical diagnostics. She serves as co-chair of the Steering Committee for the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), a public-private partnership to generate tools to improve success in developing early-stage interventions for patients who are at risk of developing schizophrenia. She is a member of the National Academies Forum on Neuroscience and Nervous System Disorders. Dr. Brady was trained in pharmacology and neuroscience. She completed her Ph.D. at Emory University School of Medicine, followed by post-doctoral work and research positions at the Uniformed Services University of the Health Sciences and the NIMH Intramural Research Program. She is the author of more than 70 peer reviewed scientific publications and is a member of the Society for Neuroscience and a Fellow and Past President of the American College of Neuropsychopharmacology. Dr. Brady has received NIH Director's Awards in recognition of her activities in biomarker development, public-private partnerships, drug development for mental disorders, collaboration and leadership of AMP® SCZ, and a National Alliance on Mental Illness Distinguished Service Award.



Laura Ana Bustamante, Ph.D. is a neuroscientist researching the cognitive processes underlying successfully achieving goals and ways to support goal attainment. With the goal of transforming the future of mental health, she integrates her lived experience of neurodivergence with formal training in clinical science and advocacy work. Her research in the field of computational psychiatry addresses challenges with cognitive function and motivation that individuals with mental health conditions sometimes experience. She is currently a staff scientist at Washington University in St. Louis in the Psychological & Brain Sciences department and earned her PhD at the Princeton Neuroscience Institute. Her goal is to integrate neurodiversity and disability perspectives into psychology and psychiatry research and practice. For example, by understanding cognition in context, targeting increased accessibility, and adopting strengths-based approaches. She has led workshops on “Neurodiversity in Academia” and “Neurodiversity Affirming Computational Psychotherapy” as well as discussing these topics on podcasts and news articles. She contributes her lived expertise to LivedX for Neuro, with an eye towards 1) increasing autonomy for mental and brain health care users, 2) decreasing stigma and bias (e.g., ableism, sanism), and 3) leveraging the tremendous potential of neuroscience to improve well-being. You can learn more about Dr. Bustamante on her personal website at: <https://www.lauraanabustamante.com/>.



Brian Fiske, Ph.D. is Chief Scientist at The Michael J. Fox Foundation for Parkinson's Research, where he has developed and led scientific strategy for over two decades. A neuroscientist by training, Brian earned his PhD from the University of Virginia with postdoctoral training at Columbia University before serving as an Associate Editor at Nature Neuroscience. At MJFF, he drives an ambitious research agenda to accelerate development of new Parkinson's therapies, championing open science and collaborative approaches to de-risk innovation. He is widely published in the field and serves on multiple international advisory committees shaping the future of neurodegenerative disease research.



Magali Haas, M.D., Ph.D. is a committed, global leader in brain health research, advocacy, and policy, with over 25 years of experience advancing precision approaches for complex brain disorders. Her career has focused on integrating disease biology, biomarkers, computational modeling, and therapeutic innovation to accelerate more targeted and effective treatments worldwide. Dr. Haas currently serves as Chief Medical Officer and a member of the Board of Directors at Psilera Inc., where she supports the development of next-generation neuroplastogens for multiple brain disorders. She is also the Founder and Board Chair of Cohen Veterans Bioscience, a nonprofit biomedical and technology research organization she led as CEO from 2012 to 2024. Under her leadership, the organization pioneered internationally recognized translational research and advocacy programs in PTSD and traumatic brain injury, catalyzing biomarker discovery, disease target validation, and cross-sector collaboration. Previously, Dr. Haas held senior bench-to-bedside leadership roles across early- and late-stage neuroscience clinical development, translational medicine, diagnostics, and integrative solutions at Johnson & Johnson. She advises national and international stakeholders as a member of the National Research Advisory Council to the U.S. Secretary of Veterans Affairs and through service on global advisory boards, including the European Platform for Neurodegenerative Diseases and IMEC. Dr. Haas earned a BS in Bioengineering from the University of Pennsylvania, an MS in Biomedical Engineering from Rutgers University, and an MD and PhD in Neuroscience, with distinction, from Albert Einstein College of Medicine.



Julie Harris, Ph.D. is the Vice President of Science Initiatives at the Allen Institute. Harris was previously Executive Vice President of Research Management at the Cure Alzheimer's Fund where she oversaw the funding strategy and research priorities for a ~\$29 million grant portfolio in support of the most promising science and scientists working to end the burden of Alzheimer's disease. Between 2011 and 2020, she worked at the Allen Institute for Brain Science as a researcher and Associate Director of Neuroanatomy where she played pivotal roles building several of the Institute's signature, foundational open science resources, including the Allen Mouse Brain Connectivity Atlas. Harris was also Vice President of Preclinical Biology at Cajal Neuroscience, a Seattle biotech startup focused on identifying therapies for neurodegenerative disease. She received a B.S. in Zoology from Michigan State University, a Ph.D. in Neurobiology and Behavior from the University of Washington, and has 50 peer-reviewed publications to her name.



Steven E. Hyman, M.D. is Harvard University Distinguished Service Professor and Harald McPike Professor of Stem Cell and Regenerative Biology and a Core Institute Member of the Broad Institute of MIT and Harvard where he directs the Broad Program in Brain Health. He is principal investigator of the Psychiatric Biomarkers Network (PBN), a multi-institutional and multi-sector consortium aimed at discovering fluid biomarkers for schizophrenia-bipolar spectrum

disorders and establishing a repository for sharing of samples and data. From 2012-2024 Hyman directed the Stanley Center for Psychiatric Research at Broad, from 2001 to 2011 he served as Provost (chief academic officer) of Harvard University, and from 1996 to 2001 he was Director of the US National Institute of Mental Health (NIMH). At NIMH he modernized its research investments, emphasizing neuroscience, emerging genomic technologies, and initiating a series of large pragmatic clinical trials to inform practice. He has served as Editor of the Annual Review of Neuroscience (2002-2016) and Chair of the International Advisory Committee on the revision of the Mental, Behavioral, or Neurodevelopmental Disorders section of the International Classification of Diseases, 11th edition, (ICD-11) for the World Health Organization (2006-2014). He was founding President of the International Neuroethics Society (2008-2013), President of the Society for Neuroscience (2015), and President of the American College of Neuropsychopharmacology (2018). He is a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a distinguished life fellow of the American Psychiatric Association, and a member of the National Academy of Medicine (NAM) where he is a member of the Forum on Neuroscience and Nervous System Disorders (chaired 2012-2018), served on the governing Council (2012-2018), and represented NAM on the governing board of the National Research Council, the operating arm of the National Academies of Sciences, Engineering, and Medicine (2016-2019). He currently chairs the Boards of Directors of the Charles A. Dana Foundation (NY) and the Wyss Center for Bio and Neuroengineering (Geneva, Switzerland). In the private sector he is a Director of Voyager Therapeutics, Cycleron Therapeutics, and Vesalius Therapeutics, and is a founder of Emugen Therapeutics. He serves on the Scientific Advisory Boards of J&J Innovative Medicines and F-Prime Capital. He received his BA, *summa cum laude*, from Yale, an MA from the University of Cambridge, which he attended as a Mellon fellow studying History and Philosophy of Science, and an MD, *cum laude*, from Harvard Medical School.



Michael C. Irizarry, M.D., M.P.H. is Senior Vice-President of Clinical Research and Deputy Chief Clinical Officer at Eisai, responsible for the overall strategy and clinical development of the neurosciences portfolio, including regulatory approvals for lecanemab and lemborexant. He earned undergraduate and medical degrees from Georgetown University and an MPH from the Harvard School of Public Health. He completed neurology residency and Memory Disorders Fellowship at Massachusetts General Hospital, and continued as Harvard Medical School faculty in the Massachusetts Alzheimer's Disease Research Center. His research encompassed

molecular mechanisms, clinical-pathological correlations, animal models, biomarkers, and epidemiology of neurodegenerative diseases, especially Alzheimer's disease. Prior to joining Eisai in 2018, Dr. Irizarry held a series of leadership positions at Eli Lilly (Vice-President, Early Clinical development, Neurosciences), and GlaxoSmithKline (including acting Vice President for Worldwide Epidemiology).



Bruce Korf, M.D., Ph.D. is the former Chair of the Department of Genetics, Associate Dean for Genomic Medicine, UAB Heersink School of Medicine; Chief Genomics Officer, UAB Medicine, and Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics. He is currently Distinguished Professor Emeritus of Genetics. Dr. Korf is past president of the Association of Professors of Human and Medical Genetics, past president of the American College of Medical Genetics and Genomics, and past president of the ACMG Foundation for Genetic and Genomic Medicine. He has served on the Board of Scientific Counselors of the National Cancer Institute and the National Human Genome Research Institute at the NIH and is currently a member of the National Advisory Council for Human Genome Research. His major research interests are genomic medicine and the natural history, genetics, and treatment of neurofibromatosis. He served as principal investigator of the Department of Defense funded Neurofibromatosis Clinical Trials Consortium, and as co-PI of the Alabama Genomic Health Initiative. He is the contact PI for the All of Us Southern Network and the UAB Undiagnosed Diseases Program, part of the NIH Undiagnosed Diseases Network. He is co-author of *Human Genetics and Genomics* (medical student textbook, now in fourth edition), co-editor Emery and Rimoin's *Principles and Practice of Medical Genetics*, and former editor-in-chief of the *American Journal of Human Genetics*. Dr. Korf received his undergraduate and medical degrees from Cornell University and obtained his PhD in Genetics and Cell Biology at Rockefeller University. He completed residency in pediatrics at Boston Children's Hospital, child neurology in the Harvard-Longwood Neurology Training Program, and genetics in the Harvard Medical School Genetics Training Program. He is certified by the American Board of Genetics and Genomics in clinical genetics, clinical cytogenetics, and clinical molecular genetics; the American Board of Pediatrics in pediatrics; the American Board of Psychiatry and Neurology in neurology (child neurology).



Dimitri Krainc, M.D., Ph.D. is the Aaron Montgomery Ward Professor and Chairman of the Davee Department of Neurology and Director of the [Feinberg Neuroscience Institute](#) and the Simpson Querrey Center for Neurogenetics. Prior to joining Northwestern in 2013, Krainc spent more than two decades at the [Massachusetts General Hospital](#) and [Harvard Medical School](#), where he completed his research and clinical training and served on faculty. He has dedicated his scientific career to studying molecular pathways in the pathogenesis of neurodegeneration. Informed by genetic causes of disease, his work has uncovered key mechanisms across different neurodegenerative disorders that have led to pioneering design and development of targeted therapies. He has received numerous awards and recognitions for his work, including the Javits Neuroscience Investigator Award and the Outstanding Investigator award from [NIH](#), and was elected to the [Association of American Physicians](#), the [National Academy of Medicine](#), and the National Academy of Inventors. He is the principal founding scientist of two biotech companies and serves as President of the [American Neurological Association](#). Dr. Krainc is a Founder of Vanqua Bio, LTI (now Bial) and a Venture Partner at OrbiMed and NeuroVC.

Precision Medicine in Neuroscience: Tools, Translation, and Implementation: A Workshop

March 4-5, 2026

Speaker Biographies



Rhoda Au, Ph.D. is Professor of Anatomy & Neurobiology, Neurology, Medicine and Epidemiology at Boston University Chobanian & Avedisian School of Medicine and School of Public Health. She serves as one of PIs of the Framingham Heart Study Brain Aging Program and Director of Neuropsychology. Her work includes using technologies to promote equal opportunity science and develop and validate globally feasible Alzheimer's disease and related dementia screening and monitoring tools as well as multi-sensor digital biomarkers. Her long-term research objective is to enable maximally inclusive solutions that shift the current focus on precision medicine to a broader emphasis on precision brain health.

Email: rhodaau@bu.edu



Michelle Colder Carras, Ph.D. is a public health scientist whose research spans epidemiology, public mental health, evidence development, and mental health services program design and evaluation. As a person with the lived experience of mental health difficulties, her research emphasizes the importance of research co-design and the implications of conducting research that is not informed by lived experience. She has been active in many advocacy activities and currently facilitates the international Transform Mental Health Research initiative, focused on building service user/client involvement and leadership in mental health research.

Email: michelle@carrasandco.com



Nilüfer Ertekin-Taner, M.D., Ph.D. is enterprise chair of the Department of Neuroscience and a professor of neurology and neuroscience at Mayo Clinic in Florida. She is a physician-scientist with seminal contributions to the field of Alzheimer's disease and related neurodegenerative conditions. Her innovative, groundbreaking work combining complex genomics and deep endophenotypes is essential for the discovery of molecular disease mechanisms, new treatments and biomarkers for these devastating and currently incurable conditions. Dr. Ertekin-Taner is recognized with the distinction of the Roy E. & Merle Meyer Professorship in Neuroscience. Dr. Ertekin-Taner earned her M.D. at Hacettepe University Medical School in Ankara, Turkey, and her Ph.D. in molecular neuroscience at Mayo Clinic Graduate School of

Biomedical Sciences. She continued her training at Mayo Clinic where she completed a neuroscience research fellowship, internal medicine and neurology residencies, and a behavioral neurology fellowship. Dr. Ertekin-Taner has pioneered the endophenotype approach in genetic studies of Alzheimer's disease and related disorders (ADRD). Her laboratory applies leading-edge analytic approaches to integrate biological traits with multi-omics data to discover precision medicine therapies and biomarkers in ADRD. Dr. Ertekin-Taner is a principal investigator of AMP-AD and Resilience-AD and was a principal investigator of M2OVE-AD consortia and Florida Consortium for African American AD Studies. She is the contact principal investigator of the CLEAR-AD U19 Program comprising 13 sites and nearly 100 investigators focused on precision medicine biomarker and therapeutic discoveries. Dr. Ertekin-Taner has been continually funded by the National Institutes of Health and foundations, having served or serving as a principal investigator on 38 grants with total extramural grant support of over \$80 million since 2008. Her lab is a leader in many national large-scale initiatives aiming to discover precision medicine therapies and biomarkers in Alzheimer's and related disorders. Owing to her prolific, impactful work, Dr. Ertekin-Taner serves/served on numerous executive committees and advisory boards, including for the National Academies of Sciences, Engineering, and Medicine and the National Institutes of Health. Dr. Ertekin-Taner is the recipient of numerous awards, including the 2022 Alzheimer's Association Zenith Fellows Award and Mayo Clinic Mid-Career Alumni Award. A board-certified neurologist, Dr. Ertekin-Taner continues to care for dementia patients. She is also a leader in education serving as director and principal investigator for Mayo Clinic Center for Clinical and Translational Science (CCaTS) KL2 Mentored Career Development Program, as founding chair of the Mayo Clinic Research Pipeline K2R Program, and as a mentor to over 80 trainees to date from various career stages.

Email: taner.nilufer@mayo.edu




Toby Ferguson, M.D., Ph.D. is Senior Vice President, Head of Neuroscience Therapeutic area at Alnylam Therapeutics. He was formerly Chief Medical Officer at Voyager since joining the company in 2024. Ferguson held positions of increasing responsibility at Biogen, most recently serving as Vice President, Head of Neuromuscular Development Unit. During his tenure, he built and developed teams focused on neuromuscular and movement disorders, overseeing strategy for these areas across Biogen R&D. Notably, he led the team that developed QALSODY® (tofersen), the first genetically targeted therapy for SOD1 amyotrophic lateral sclerosis (ALS); this therapeutic received the first accelerated approval based on reduction of neurofilament, a surrogate biomarker pioneered by Ferguson, his team, and the broader ALS community. Overall, his teams at Biogen were responsible for nine successfully executed INDs and three proof-of-concept clinical trials and filings. Prior to joining Biogen, Ferguson was Assistant Professor of Neurology, Shriners Pediatric Research Center and Temple University School of Medicine. He received his M.D. and Ph.D. from University of Florida College of Medicine and his B.S. from University of Florida, Gainesville. He also completed a residency in neurology and a neuromuscular fellowship at the University of Pennsylvania.

Email: fergusontobya@gmail.com



Mariano Gabitto, Ph.D. joined the Allen Institute as an Assistant Investigator in 2021. He currently co-leads the data analysis efforts of the Seattle Alzheimer's Disease Atlas (SEA-AD), aiming to characterize the neuropathological, molecular, and spatial changes taking place in AD. Previously, Mariano held a research scientist position at U.C. Berkeley, working with Mike Jordan and Nir Yosef to develop machine learning algorithms to integrate multimodal genomic data. With Mike Jordan, Mariano created Bayesian statistical models to reconcile super-resolution microscopy data, work for which they received the Michell Prize in applied statistics. Before this work, he was a joint postdoctoral fellow in the groups of Rich Bonneau (Simons Foundation) and Gord Fishell (Broad Institute). With them, Mariano investigated the mechanisms specifying the identity of cortical interneurons by developing statistical tools to characterize chromatin accessibility and gene regulatory networks. Mariano completed his Ph.D. in Neuroscience at Columbia University, where he worked with Charles Zuker creating computational tools to decipher the coding mechanisms of cortical taste sensation, and with Larry Abbott and Liam Paninski, developing Bayesian models to catalog spinal cord interneurons.



Daniel Geschwind, M.D., Ph.D. is the Gordon and Virginia MacDonald Distinguished Professor of Neurology, Psychiatry and Human Genetics at UCLA. In his capacity as Senior Associate Dean and Associate Vice Chancellor of Precision Health, he leads the Institute for Precision Health (IPH) at UCLA. In his laboratory, his group has pioneered the application of systems biology methods in neurologic and psychiatric disease, with a focus on autism spectrum disorders (ASD) and neurodegenerative conditions. His laboratory has made major contributions to identifying genetic causes of autism spectrum disorder, defining the molecular pathology of autism and allied psychiatric disorders, and has worked to increase diversity in autism research. His work in dementia is focused on the mechanisms of tauopathies, where his laboratory is developing novel therapeutic approaches. He sits on editorial boards of *Cell*, *Science* and *Neuron*, and is among the highest cited neurologists in the world. He has received several awards for his laboratory's work including the American Neurological Association (ANA) Derek Denny-Brown Neurological Scholar Award, most recently the Society of Biological Psychiatry Gold Medal Award and the American Academy of Neurology's 2022 Cotzias Lecture and Award. He is the 2022 National Academy of Medicine recipient of the Rhoda and Bernard Sarnat International Prize in Mental Health. He is an elected Member of the American Association of Physicians and the National Academy of Medicine.



Tristan Glatard, Ph.D. is Scientific Director of the Krembil Centre for Neuroinformatics, Inaugural BMO Chair in AI and Mental Health, and a Senior Scientist at the Centre for Addiction and Mental Health (CAMH) in Toronto. He is also Professor (status-only) in the Department of Psychiatry and Associate Member (status-only) in the Department of Computer Science at the University of Toronto (UofT). Additionally, Tristan holds an ongoing appointment as a Professor in the Department of Computer Science and Software Engineering at Concordia University in Montreal, where he held a Tier II Canada Research Chair in Big Data for Neuroinformatics and served as co-director of the Applied AI Institute. He has also served as a Visiting Scholar at McGill University, a Research Scientist at the French National Centre for Scientific Research, and completed a Postdoctoral Fellowship at the University of Amsterdam. Tristan earned an Engineering degree from École Centrale de Lyon in France in 2004, followed by a Master of Science in Images and Systems from the same institution, and a PhD in Computer Science from the University of Nice Sophia-Antipolis in 2007. In 2022, he was elected to the Royal Society of Canada College of New Scholars.

Email: tristan.glatard@camh.ca



Jamie Heywood is the CEO and Founder of Alden Scientific, a research institute applying artificial intelligence and advanced multi-omic biology to individual health, disease, and aging. An MIT-trained mechanical engineer, he entered biomedicine after his brother Stephen's ALS diagnosis in 1999, an event that shaped his career-long focus on reengineering how discovery and care are done. Over the past two decades, he has founded or co-founded six companies, including the ALS Therapy Development Institute, PatientsLikeMe, and AOBiome. His work has driven innovations in clinical trial design, real-world evidence, and first-in-class therapeutics, and has been profiled in *Nature*, *The New Yorker*, *The New York Times*, and *The Wall Street Journal*.

Email: jamie@aldenscientific.com



Martien Kas, Ph.D. is Professor of Behavioral Neuroscience at the Groningen Institute for Evolutionary Life Sciences at the University of Groningen, the Netherlands. The research of his group aims to develop a transdiagnostic and translational neurobiological approach to the understanding of neuropsychiatric disorders to accelerate the discovery and development of better treatments. To realise this ambition, he has implemented an innovative transdiagnostic strategy that also allows for back translation of human quantitative biological findings to animals to test for causality, to expand our knowledge of the underlying neurobiological mechanism, and to facilitate the drug discovery process. Novel technologies have been developed and validated to stimulate this approach, including a smartphone application to assess real world daily social functioning (<https://www.behapp.com/>). From 2022 to 2025, Kas was the

President of the European College of NeuroPsychopharmacology (ECNP) where he initiated and is leading the Precision Psychiatry Roadmap initiative and the biomarker mapping exercise for mental disorders. He is also editorial board member of Mammalian Genome, and was the project coordinator of the PRISM1 and PRISM2 projects, two large EU Innovative Medicine Initiative (IMI) projects that aimed to unpick the biological reasons underlying social dysfunction, which is a common early symptom of Schizophrenia, Alzheimer's disease and Major Depressive Disorder. Since 2024, he is also a member of the Future Diagnostic and Statistical Manual of Mental Disorders (DSM) Strategic Committee. He has authored over 250 peer-reviewed publications in this research field.

Email: m.j.h.kas@rug.nl



Nita A. Limdi Pharm.D., Ph.D., M.S.P.H. is a clinical pharmacist and chronic disease epidemiologist with over 25 years of experience in clinical pharmacy, pharmacogenomics, and genomic medicine implementation. She is the Ray L. Watts Heersink Endowed Chair in Neurology and Associate Dean for Genomic Medicine at the University of Alabama at Birmingham (UAB) and directs the statewide Alabama Genomic Health Initiative (AGHI), a nationally recognized program integrating genomic medicine into clinical care across all 67 Alabama counties. An internationally recognized leader in pharmacogenomics, Dr. Limdi's foundational research on anticoagulation therapy—particularly warfarin—has shaped genotype-guided dosing guidelines used worldwide. She holds leadership roles in national initiatives including the NIH-funded eMERGE and IGNITE networks and is a key contributor to CPIC guideline development. Dr. Limdi is also a highly regarded mentor and directs multiple NIH-funded training programs focused on advancing genomic medicine research and implementation.

Email: nlimdi@uab.edu



Hussein K. Manji, M.D., FRCPC is co-chair of the UK Government Mental Health Mission, professor at the Department of Psychiatry at Oxford University and visiting professor, Department of Psychiatry, at Duke. Previously he served as Global Head, Science for Minds at Johnson & Johnson, one of the world's largest healthcare companies, and Global Therapeutic Head for Neuroscience, Janssen Pharmaceutical Companies of Johnson & Johnson. Before Johnson & Johnson, Manji was Chief of the Laboratory of Molecular Pathophysiology at the National Institutes of Health (NIH) and director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. "Dr. Manji has been a long-standing colleague and collaborator of faculty within the department," said John H. Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and professor of psychiatry, of neuroscience, and of psychology, and chair of the Yale Department of Psychiatry. "We are thrilled to strengthen these relationships and to provide new opportunities for our trainees with this faculty appointment." The major focus of Manji's research is the investigation of disease and treatment-induced changes in synaptic and neural

plasticity in neuropsychiatric disorders. Building on the work at Yale, his research with Dennis Charney, MD, then at the National Institute of Mental Health Intramural Research Program, identified the efficacy of ketamine for treatment-resistant depression. At Janssen, Manji provided visionary leadership that led to the FDA approval of Esketamine, the first mechanistically novel U.S. Food and Drug Administration-approved antidepressant in over half a century. In 2023 the National Academy of Medicine honored Manji, Krystal, and Charney with the Rhoda and Bernard Sarnat International Prize in Mental Health, which since 1992 has been presented to individuals, groups, or organizations that have demonstrated outstanding achievement in improving mental health. All three are members of the National Academy of Medicine. Manji is a member of the National Institutes of Health Novel and Exceptional Technology and Research Advisory Committee, the World Dementia Council, the World Economic Forum (WEF) Global Future Councils, the Board of Mass General-Brigham Incorporated; the Board of Trustees of Harvard University/McLean Hospital, the Board of the Dana Foundation, the Scientific Advisory Board of the Stanley Center at the Broad Institute of MIT and Harvard. He is recent chair of the National Academy of Medicine Neuroscience, Behavior, Brain Function & Disorders group, co-chair of the Healthy Brains Global Initiative, and has held numerous leadership positions within the NIH, NAM, the FNIB Biomarkers Consortium Executive Committee. He has received numerous prestigious awards, including the NIMH Director's Career Award for Significant Scientific Achievement, PhRMA Research & Hope Award for Excellence in Biopharmaceutical Research, the American Federation for Aging Research Award of Distinction, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the ACNP's Joel Elkes Award for Distinguished Research, the DBSA Klerman Senior Distinguished Researcher Award, the Briggs Pharmacology Lectureship Award, the Caring Kind Alzheimer's Disease Leadership Award, and the Global Health & the Arts Award of Recognition.



Valentina Mantua, M.D., Ph.D. is a medical doctor and psychiatrist with a PhD in neurobiology and over fifteen years of experience in regulatory science. Between 2012 and 2019, she served as a delegate to several committees and working parties of the European Medicines Agency (EMA). Dr. Mantua joined the U.S. Food and Drug Administration (FDA) in 2019 and currently serves as Associate Director of Regulatory Science at the Office of Neuroscience, CDER, where she oversees regulatory review and policy development for neurological and psychiatric products. Dr. Mantua is passionate about advancing precision

neuroscience and actively pursues initiatives across scientific societies and in the pre-competitive space to develop innovative approaches that enable more targeted and personalized treatments in neuroscience.

Email: valentina.mantua@fda.hhs.gov



Kenneth Marek, M.D. is President and senior scientist at the Institute for Neurodegenerative Disorders. Dr. Marek's major research interests include identification of biomarkers for early detection, assessment of disease progression and development of new treatments for neurodegenerative disorders including neuronal synuclein disease (Parkinson disease and Dementia with Lewy Bodies), Alzheimer disease and related neurodegenerative disorders. He has authored numerous neurology and neuroscience publications on these topics. Dr. Marek has and continues to be the principal investigator of several ongoing multi-center international studies (including the Parkinson Progression Marker Initiative (PPMI) and the Parkinson Associated Risk Syndrome (PARS) study. Dr. Marek serves as a special scientific advisor to The Michael J. Fox Foundation. He has served in leadership roles in several organizations focused on neurodegenerative disorders and has been the recipient of numerous grants to support his work in Parkinson disease, Alzheimer Disease and Huntington disease including the Robert A. Pritzker Prize for Leadership in Parkinson's Research. He also was a co-founder of Molecular NeuroImaging, LLC, and Xing imaging LLC companies providing discovery and clinical neuroimaging research services.

Email: kmarek@indd.org



Hugh Marston Ph.D., FRSB, FECNP, FBPharm, Prof. is currently SVP and Head of Global Neuroscience & Mental Health Discovery Research at Boehringer Ingelheim, based in Biberach, Germany. Boehringer's focus is on innovative approaches in mental health, with a range of first-in-class programmes currently in development. These programmes are increasingly based on a systems and circuits understanding of human disorders, striving to bring an ever-increasing level of precision to psychiatry. Following a PhD in experimental psychopharmacology at Cambridge University, Hugh completed fellowships at NIDA and Edinburgh University. Moving to Organon (which became Schering Plough then Merck), he was Head of Neurobiology, where the neuropsychiatry team brought *asenapine* and *sugammadex* to market, and a range of innovative programmes into clinical trials. He then headed Pharmacology at TPP Pharma, a micropharma acquired by Merck as IOMet, with clinic-ready assets developed from scratch. He then moved to Lilly as Head of Translational Neuroscience, reflecting his long-standing interest in reverse translation from the clinic. Hugh is actively involved in a number of large-scale initiatives to develop neuroscience and improve patient care in psychiatry; for example, he was the project leader, from inception, of the Innovative Medicine Initiative PRISM1 & 2 projects, seeking transdiagnostic, quantitative biological phenotypes across central nervous system disorders. He maintains an active interest in academic research, both directly with the University of Groningen in the Netherlands, and through multiple collaborations with UK, European and US universities and institutions.



Soeren Mattke M.D., DSc. is a Research Professor of Economics at the University of Southern California and the Director of the USC Brain Health Observatory. The Observatory works on health system aspects of brain disorders with a focus on Alzheimer's disease. So far, the Observatory has published analyses of health system preparedness to deliver a disease-modifying Alzheimer's treatment in 14 countries as well as analyses of diagnostic technologies and the economics of those treatments. Dr. Mattke serves on the Editorial Boards of *Alzheimer's & Dementia* and the *Journal of*

Alzheimer's Disease, on ADI's Medical and Scientific Advisory Panel, the CTAD and CEOi Workgroups on Blood Based Biomarkers and Digital Cognitive Tests and a Consensus Panel for early detection of cognitive impairment in primary care. Dr. Mattke has authored over 200 peer reviewed journal papers and technical reports. Prior to joining USC, Dr. Mattke was a Senior Scientist at RAND Health, a global think tank, where he led the private sector healthcare practice, and worked at the OECD in Paris on benchmarking healthcare systems in industrialized countries, in the healthcare practice of Bain & Company in Boston, at Abt Associates, a policy consulting firm in Cambridge, MA, and at Harvard University. He trained as an internist and cardiologist at the University of Munich and got his doctoral degree in health policy at Harvard.

Email: mattke@usc.edu



Nathaniel Mohatt, Ph.D. joined ARPA-H as a Program Manager in January 2025. A community psychologist, Mohatt's focus is on increasing health and well-being from brain to community. He leads the Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) program, and is pursuing new advances in sleep health, suicide prevention, and neuromodulation. Mohatt completed his doctorate at the University of Alaska Fairbanks, with a postdoctoral fellowship in substance abuse prevention at Yale University School of Medicine. He has served as

faculty at Yale and the University of Colorado Anschutz, advised for the Military Operational Medicine Research Program, and, led community-based suicide prevention research team at the VA. While at the VA, he co-chaired the development of the VA's National Community-Based Suicide Prevention Program. Prior to joining ARPA-H, he worked as a lead scientist and advisor at Booz Allen Hamilton, supporting programs in suicide prevention and neuroscience at the Defense Advanced Research Projects Agency.

Email: nate.mohatt@arpa-h.gov



Frederike Petzschner, Ph.D. is an Assistant Professor at the Department of Cognitive and Psychological Sciences and co-director of the Brainstorm Program at the Carney Institute for Brain Science at Brown University. The Brainstorm Program accelerates the translation of computational brain science to clinical applications and commercialization. Prior to this, Frederike worked at the Translational Neuromodeling Unit at the University of Zurich and ETH Zurich with Prof. Klaas Enno Stephan. Her research in the PEAC Lab (Psychiatry, Embodiment and Computation Lab)

focusses on human perception and mental health: She uses mathematical models in combination with behavior and brain imaging to understand brain-body and brain-world interactions in the healthy population and in patients suffering from psychosomatic symptoms, Disordered Gambling, Obsessive-Compulsive Disorder and Chronic Pain. Before coming to Zurich, Frederike received a Master with Honors degree in Physics at the University of Würzburg and a PhD with Stefan Glasauer in systemic Neuroscience at the LMU Munich. She graduated both programs of the Bavarian Elite Network with the highest possible distinction. Besides her academic interest, Frederike is a member of the national council for digital ecology in Germany (Rat für digitale Ökologie), an alumni of the WEF Global Shapers.

Email: frederike_petzschner@brown.edu



Kathleen Poston, M.D. is the Edward F. and Irene Thiele Pimley Professor in Neurology and Neurological Sciences and (by courtesy) Neurosurgery at Stanford University. She received her Bachelor's of Science in Bioengineering at the University of Pennsylvania, her Master's Degree in Biomedical Engineering and her MD at Vanderbilt University. She completed her Neurology residency training at UCSF, completed a fellowship in clinical Movement Disorders at Columbia University and postdoctoral research training in Functional Neuroimaging at the Feinstein

Institute. Dr. Poston's research and clinical emphasis is biomarker development to study the motor and non-motor impairments symptoms, such as dementia, that develop in patients with Parkinson's disease and Lewy body dementia. Dr. Poston is Vice-Chair for Research in the Department of Neurology, Chief of the Movement Disorders Division and holds an appointment in the Memory Disorders division. She is a founding member of the Stanford Alzheimer's Disease Research Center and co-Director for the Lewy Body Dementia Association Research Center of Excellence at Stanford University, and Director of the Stanford Parkinson's Foundation Center of Excellence.



Larisa Reyderman, Ph.D. is Vice President and the Global Head of Clinical Pharmacology and Translational Medicine at Eisai Inc in Woodcliff Lake, New Jersey. She is a graduate of University of Pennsylvania and received her PhD in pharmaceuticals research from The University of Texas at Austin. Prior to joining Eisai, Dr Reyderman worked at Schering-Plough in Kenilworth, New Jersey where she was responsible for overseeing early clinical research and experimental medicine programs in a variety of indications and disease states. Dr Reyderman's career has been focused largely in neurology as well as oncology clinical and pharmacology research, working on dozens of clinical study designs and overseeing numerous clinical trials. Accomplishments for Dr Reyderman include contributing to a number of successful regulatory approvals co-authoring of over 50 scientific publications and abstracts.



Reisa Sperling, M.D., MMSc. is a neurologist focused on the detection and treatment of Alzheimer's disease (AD) at the earliest possible stage, even before clinical symptoms are apparent. Dr. Sperling is a Professor in Neurology at Harvard Medical School, and the Director of the Center for Alzheimer Research and Treatment (CART) at Brigham and Women's Hospital and Massachusetts General Hospital. Dr. Sperling is the co-Principal Investigator (with her husband Keith Johnson) of the NIH funded Harvard Aging Brain Study. Dr. Sperling chaired the 2011 NIA-Alzheimer's Association workgroup to develop guidelines for the study of "Preclinical Alzheimer's disease," and co-led the workgroup that defined "Amyloid Related Imaging Abnormalities (ARIA) the same year. She co-led the Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease (A4) Study, the first prevention trial in sporadic preclinical ("presymptomatic") AD, and the companion LEARN Study, and has made the A4/LEARN longitudinal data publicly available to researchers from around the world. Dr. Sperling co-leads the NIH funded Alzheimer's Clinical Trial Consortium (ACTC), and the public-private partnership AHEAD 3-45 Study prevention trials, testing targeted dosing of lecanemab in early and late stages of preclinical AD. Dr. Sperling has long sought to change the way the scientific community and the public thinks about AD, generating compelling evidence that there is a long preclinical phase of the disease, marked by the accumulation of early AD pathology and gradual cognitive decline that begins more than a decade prior to clinically evident impairment. Her foundational work combines molecular PET imaging of amyloid and tau pathology and innovative neuropsychological measures to predict and track cognitive decline. She has made seminal contributions to the design of disease-modifying trials across the spectrum of AD, including work to understand and reduce the risk of ARIA, and the importance of treating much earlier in the pathophysiological process of AD. Dr. Sperling also works on understanding the interaction of vascular disease with AD pathology, including the impact of vascular risk on tau accumulation. Her most recent studies expand into plasma biomarkers and smart phone cognitive assessments, working towards future combination prevention trials. Dr. Sperling received the 2015 Potamkin Prize from the American Academy of Neurology, the 2018 Raymond Adams Lectureship Award from the American Neurological Association and was elected to the National Academy of Medicine in 2021.

Email: reisa@bwh.harvard.edu



Diane Stephenson, Ph.D. is a neuroscientist by training with 35 years combined experience in academic neuroscience and drug discovery. Dr. Stephenson received her undergraduate degree in Biochemistry at University of California and her Ph.D. in Medical Neurobiology from Indiana University. She spent the majority of her career as a translational neuroscientist at the largest pharmaceutical companies focusing on disease areas including Alzheimer's, Parkinson's, Stroke, ALS and Autism Spectrum Disorders. Dr Stephenson joined Critical Path Institute in 2011 and leads public private partnerships with the goal of accelerating regulatory endorsed drug development tools for neurodegenerative diseases. She currently leads Critical Path Institute's initiatives focused on Parkinson's disease (CPP) and Alzheimer's disease (CPAD) with a mission to raise the urgency for much needed tools and treatments that focus on early intervention. Her passion centers around putting the patient voice front and central to all stages of drug development and research.

Email: dstephenson@c-path.org



Julian Tillmann, Ph.D. is a Principal Clinical Scientist at F.Hoffmann-La Roche Ltd. with over a decade of combined clinical research and drug development experience in neuroscience in neurodevelopmental disorders and neurodegenerative diseases. After completing five years of post-doctoral training at King's College London—where he contributed to the largest mental health grant for autism stratification biomarkers—Julian joined Roche in 2021. He has since spearheaded clinical endpoint strategies across the Neurodevelopmental Disorder (NDD) portfolio, notably leading endpoint development for Phase I-III trials in autism, Angelman Syndrome, and Dup15q. He was the Clinical Team Lead for alogabat to oversee clinical development activities and the read-out of the Ph2 clinical trial in Autism Spectrum Disorders. Julian recently transitioned to Basel to take on a Principal Clinical Scientist role to develop treatments in Alzheimer's Disease. Beyond molecule-specific work, Julian holds several strategic leadership roles, including EFPIA Lead for AIMS-2-TRIALS, ABOM Steering Committee in Angelman Syndrome and co-founder of a working group focused on advancing psychometric methods for clinical trials. He has authored over 50 peer-reviewed publications.

Email: julian.tillmann@roche.com



Elisabetta Vaudano, D.V.M., Ph.D. is an Italian-trained Doctor of Veterinary Medicine with an MSc in Animal Laboratory Science and a PhD in Molecular Neurobiology obtained through studies in Italy and the United Kingdom. She has developed a strong expertise in translational research and neuroscience through more than a decade of work in leading academic institutions across the UK and Scandinavia. Subsequently, Elisabetta advanced her career in research and innovation management within the pharmaceutical and biotechnology industries in Denmark, holding positions of increasing responsibility. Since 2010, she has served at the Innovative Medicines Initiative and its successor, the Innovative Health Initiative (IHI), where she currently holds a senior scientific role. In this capacity, she oversees the organization's scientific strategy and the neuroscience portfolio, with extensive experience in alliance management, stakeholder engagement, public-private partnerships, and the coordination of complex international research consortia within European research frameworks.

Email: elisabetta.vaudano@ihi.europa.eu



Scott W. Woods, M.D. is a psychiatrist and a principal investigator for the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership Schizophrenia (AMP SCZ) Observational Study of youth at clinical high risk (CHR) for psychosis and for the AMP SCZ Proof of Principle clinical trials for CHR.

Email: scott.woods@yale.edu

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

Purpose

To prohibit discrimination, harassment, and bullying for all participants in National Academies activities.

Applicability

All participants in all settings and locations in which the National Academies work and activities are conducted.

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

The National Academies of Sciences, Engineering, and Medicine (National Academies) are committed to the principles of integrity, civility, and respect in all of our activities. We look to you to be a partner in this commitment by helping us to maintain a professional and cordial environment. **All forms of discrimination, harassment, and bullying are prohibited in any National Academies activity.** This policy applies to all participants in all settings and locations in which the National Academies work and activities are conducted, including committee meetings, workshops, conferences, and other work and social functions where employees, volunteers, sponsors, vendors, or guests are present.

Definitions

Discrimination is prejudicial treatment of individuals or groups of people based on their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws.

Sexual harassment is unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature that creates an intimidating, hostile, or offensive environment.

Other types of harassment include any verbal or physical conduct directed at individuals or groups of people because of their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws, that creates an intimidating, hostile, or offensive environment.

Bullying is unwelcome, aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment.

Reporting and Resolution

Any violation of this policy should be reported. If you experience or witness discrimination, harassment, or bullying, you are encouraged to make your unease or disapproval known to the individual at the time the incident occurs, if you are comfortable doing so. You are also urged to report any incident by:

- Filing a complaint through the National Academies Complaint Intake Form (<https://nas.hracity.net/webform/index/a5ed0226-f5e5-4da4-be0d-1daf8976f594>), and/or
- Filing a complaint with the Office of Human Resources at 202-334-3400 or hrservicecenter@nas.edu, or
- Reporting the incident to an employee involved in the activity in which the member or volunteer is participating, who will then file a complaint with the Office of Human Resources.

Complaints should be filed as soon as possible after an incident. To ensure the prompt and thorough investigation of the complaint, the complainant should provide as much information as is possible, such as names, dates, locations, and steps taken. The Office of Human Resources will investigate the alleged violation in consultation with the Office of the General Counsel.

If an investigation results in a finding that an individual has committed a violation, the National Academies will take the actions necessary to protect those involved in its activities from any future discrimination, harassment, or bullying, including in appropriate circumstances **the removal of an individual from current National Academies activities and a ban on participation in future activities.**

Confidentiality

Information contained in a complaint is kept confidential, and information is revealed only on a need-to-know basis. The National Academies will not retaliate or tolerate retaliation against anyone who makes a good faith report of discrimination, harassment, or bullying.

Responsible Party

The NRC Executive Officer is responsible for oversight of and substantive changes to the policy.

FORUM/ROUNDTABLE INFORMATION

Forum on Neuroscience and Nervous System Disorders

The **Forum on Neuroscience and Nervous System Disorders** was established in 2006 to provide a venue for building partnerships, addressing challenges, and highlighting emerging issues related to brain disorders, which are common, major causes of premature mortality, and, in aggregate, the largest cause of disability worldwide. The Forum’s meetings bring together leaders from government, industry, academia, disease advocacy organizations, philanthropic foundations, and other interested parties to examine significant—and sometimes contentious—issues concerning scientific opportunities, priority setting, and policies related to research on neuroscience and brain disorders; the development, regulation, and use of interventions for the nervous system; and related ethical, legal, and social implications.

Forum members meet several times a year to exchange information, ideas, and differing perspectives. The Forum also sponsors workshops (symposia), workshop proceedings, and commissioned papers as additional mechanisms for informing its membership, other stakeholders, and the public about emerging issues and matters deserving scrutiny. Additional information is available at www.nas.edu/NeuroForum.

MEMBERS

Frances Jensen, MD, co-chair
University of Pennsylvania

Deanna Barch, PhD, co-chair
Washington University in St. Louis

Amy Bany Adams, PhD
National Institute of Neurological Disorders and Stroke

Trevor Archer, PhD
National Institute of Environmental Health Sciences

Bruce Bebo, PhD
National Multiple Sclerosis Society

Andrea Beckel-Mitchener, PhD
National Institute of Mental Health

Diane Bovenkamp, PhD
BrightFocus Foundation

Katja Brose, PhD
Chan Zuckerberg Initiative

Teresa Buracchio, MD
Food and Drug Administration

Sarah Caddick, PhD
Gatsby Charitable Foundation

Rosa Canet-Avilés, PhD
California Institute for Regenerative Medicine (CIRM)

Michael Chiang, MD
National Eye Institute

Merit Cudkowicz, MD, MSc
Harvard Medical School;
Massachusetts General Hospital

Beverly Davidson, PhD
Children’s Hospital of Philadelphia

M. Denise Dearing, Ph.D
National Science Foundation

Nita Farahany, JD, PhD
Duke University

Eva L. Feldman, MD, PhD
University of Michigan

Brian Fiske, PhD
The Michael J. Fox Foundation for Parkinson’s Research

Magali Haas, MD, PhD, MSE
Cohen Veterans Bioscience

Julie Harris, PhD
Allen Institute

H.E. Hinson, MD, MCR
American Academy of Neurology

Richard Hodes, MD
National Institute on Aging

Stuart W. Hoffman, PhD
Department of Veterans Affairs

Yasmin Hurd, PhD
Icahn School of Medicine at Mount Sinai

Michael L. Hutton, PhD
Eli Lilly & Company

Steven E. Hyman, MD
Broad Institute of MIT and Harvard

Michael Irizarry, MD
Eisai

Sahib Khalsa, MD, PhD
University of California, Los Angeles; American College of Neuro-psychopharmacology

George Koob, PhD
National Institute on Alcohol Abuse and Alcoholism

Dimitri Krainc, MD, PhD, FANA
Northwestern University Feinberg School of Medicine

John Krystal, MD,
Yale University

Robert C. Malenka, MD, PhD
Stanford University

Husseini Manji, MD, FRCPC
Oxford University; Duke University; Yale University; UK Gov't Mental Health Goals Program

Bill Martin, PhD
Janssen Research & Development

Caroline Montojo, PhD
Dana Foundation

John H. Morrison, PhD
Society for Neuroscience

John J. Ngai, PhD
National Institute of Health's Brain Research through Advancing Innovative Neurotechnologies (BRAIN®) Initiative

Sanjeev Pathak, MD
Acadia Pharmaceuticals

Gentry Patrick, PhD
University of California San Diego

Steve Marc Paul, MD
Seaport Therapeutics

Sri Ramulu Pullagura, PhD
Foundation for the NIH

Marsie Ross, PharmD
Harmony Biosciences

Katie Sale, BA
American Brain Coalition

Raymond Sanchez, MD
Bain Capital Life Sciences

Terrence Sejnowski, PhD
Salk Institute for Biological Studies

Joan Sereno, PhD
National Science Foundation

Sarah Shnider, PhD, MSc
One Mind

David Shurtleff, PhD
National Center for Complementary and Integrative Health

John Spiro, PhD
Simons Foundation

Nora D. Volkow, MD
National Institute on Drug Abuse

Christopher Weber, PhD
Alzheimer's Association

Doug Williamson, MBChB, MRCPsych
Independent Consultant

Gary Wilson, PhD
Huo Family Foundation

Xiaolin Zheng, PhD
U.S. Food and Drug Administration

Stevin Zorn, PhD
MindImmune Therapeutics

Forum Staff

Sheena Posey Norris, MS, PMP
Forum Director
Senior Program Officer

Ashley Pitt, BA
Senior Program Assistant

Clare Stroud, PhD
Senior Board Director,
Board on Health Sciences Policy

Recent Events

[Understanding Brain-Body Interactions to Advance Brain Health \(October 22-23, 2025\)](#)

[Unraveling the Neurobiology of Empathy and Compassion: Implications for Treatments for Brain Disorders and Other Applications \(May 19 and 21, 2025\)](#)

[Applying Neurobiological Insights on Stress to Foster Resilience Across the Lifespan \(March 24-25, 2025\)](#)

Forum Sponsors and Participating Organizations

GOVERNMENT

California Institute for Regenerative Medicine	National Institute of Neurological Disorders and Stroke
Department of Veterans Affairs	National Institute on Aging
Food and Drug Administration	National Institute on Alcohol Abuse and Alcoholism
National Center for Complementary and Integrative Health	National Institute on Drug Abuse
National Eye Institute	National Institutes of Health BRAIN Initiative
National Institute of Environmental Health Sciences	National Science Foundation
National Institute of Mental Health	

INDUSTRY

Acadia Pharmaceuticals	Harmony Biosciences
Eisai	Janssen Research & Development, LLC
Eli Lilly and Company	QurAlis

NONPROFIT ORGANIZATIONS

Alzheimer's Association	Huo Family Foundation
American Brain Coalition	Michael J. Fox Foundation for Parkinson's Research
BrightFocus® Foundation	National Multiple Sclerosis Society
Cohen Veterans Bioscience	One Mind
Dana Foundation	Paul G. Allen Frontiers Group
Foundation for the National Institutes of Health	Simons Foundation Autism Research Initiative

PRIVATE FOUNDATION

Gatsby Charitable Foundation

PROFESSIONAL SOCIETY

American Academy of Neurology
 American College of Neuropsychopharmacology
 American Neurological Association
 Society for Neuroscience



ABOUT THE FORUM

The Forum on Drug Discovery, Development, and Translation (the forum) of the National Academies of Sciences, Engineering, and Medicine (the National Academies) was created in 2005 by the National Academies Board on Health Sciences Policy to foster communication, collaboration, and action in a neutral setting on issues of mutual interest across the drug research and development lifecycle. The forum membership includes leadership from the National Institutes of Health, the U.S. Food and Drug Administration, industry, academia, consortia, foundations, journals, and patient groups.

Through the forum's activities, participants have been better able to bring attention and visibility to important issues, explore new approaches for resolving problem areas, share information and find common ground, and work together to develop ideas into concrete actions and new collaborations.

Forum work is based on four thematic priorities:

Spurring **INNOVATION** and **IMPLEMENTATION**

Revolutionary advances in biomedical research and technology present new and exciting opportunities for the discovery and development (R&D) of new therapies for patients. The evolution of health care is expanding possibilities for integration of clinical research into the continuum of clinical care and new approaches are enabling the collection of data in real-world settings. Innovative modalities, such as digital health technologies and artificial intelligence applications, can now be leveraged to overcome challenges and advance clinical research. The forum unites key stakeholders to identify opportunities, address bottlenecks, and spur innovation in drug discovery, development, and translation.

Increasing **PERSON-CENTEREDNESS**

There is much greater awareness around the need for more person-centered approaches that prioritize lived experience and justice in the discovery, development, and translation of new treatments. The forum seeks to center priorities of people living with disease and those who have been traditionally excluded from the clinical trials enterprise, advance the science of patient input, and help bring to fruition innovations that better address the needs of patients.

Promoting **COLLABORATION** and **HARMONIZATION**

The forum provides a neutral platform for communication and collaboration across sectors and disciplines to better harmonize efforts throughout the drug R&D life cycle. It does this by convening a broad and evolving set of stakeholders to help integrate patients, caregivers, researchers, trialists, community practitioners, sponsors, regulators, payers, patient groups, and others into the continuum of research and clinical care. The forum also strives to enable shared decision-making and ensure that patients have input into research questions, researchers have insight into clinical practice, and practitioners are engaged in the clinical trials enterprise.

Enhancing the **WORKFORCE** and **INFRASTRUCTURE**

The forum has fostered the development of strategies to improve the discipline of innovative regulatory science and continues to focus on building a workforce that is adaptable and resilient. Considerable opportunities remain to improve and expand the evolving clinical trials workforce and infrastructure, integrate community-based practices, and engage early-career scientists and clinicians in drug discovery, development, and translation. The forum will continue to anticipate and promote adaptation to changes in the infrastructure of health care delivery.

For more information about the Forum on Drug Discovery, Development, and Translation, please visit at:

[NATIONALACADEMIES.ORG/DRUGFORUM](https://www.nationalacademies.org/drugforum)

Forum Membership

Klaus Romero (Co-Chair)

Critical Path Institute

Ann Taylor (Co-Chair)

Retired

Richardae Araojo

Araojo Advisory Group LLC

Ronald Bartek

Friedreich's Ataxia Research Alliance

Barbara E. Bierer

Harvard Medical School

Linda S. Brady

National Institute of Mental Health, NIH

Lynda Chin

Apricity Health, Inc.

Luther T. Clark

Merck & Co., Inc.

Tammy R.L. Collins

Burroughs Wellcome Fund

James T. Dalton

University of Alabama

Sneha Dave

Generation Patient

Richard T. Davey

National Institute of Allergy and Infectious Diseases, NIH

Katherine Dawson

Biogen

James H. Doroshow

National Cancer Institute, NIH

Jeffrey M. Drazen

New England Journal of Medicine

Steven Galson

Boston Consulting Group

Carlos Garner

Eli Lilly and Company

Kenneth Getz

Tufts Center for the Study of Drug Development

David J. Glass

Regeneron Pharmaceuticals

Morgan Hanger

Clinical Trials Transformation Initiative

Tesheia Harris

Clinical Trials Access Collaborative

Penny M. Heaton

Johnson & Johnson

Sally L. Hodder

West Virginia University

Patrik Johansson

Washington State University

Julie Johnson

The Ohio State University

Lytic A. Jorgenson

Office of the Director, NIH

Esther Krofah

Milken Institute

Peter Lee

University of California, Davis School of Law

Anna S.F. Lok

University of Michigan

Martin Mendoza

Centers for Medicare and Medicaid Services

Joseph P. Menetski

Foundation for the NIH

Mark N. Namchuk

Harvard Medical School

Anaeze C. Offodile II

Memorial Sloan Kettering Cancer Center

Heather Pierce

Association of American Medical Colleges

Howard B. Rosen

Stanford University

Joni Rutter

National Center for Advancing Translational Sciences, NIH

Mark Taisey

Amgen Inc.

Amir Tamiz

National Institute of Neurological Disorders and Stroke, NIH

Pamela Tenaerts

Medable

Cris Woolston

Sanofi

Joseph C. Wu

Stanford University School of Medicine

Forum Staff

Carolyn Shore

Forum Director

Mike Berrios

Senior Program Assistant



Roundtable on **GENOMICS** and **PRECISION HEALTH**

The sequencing of the human genome is rapidly opening new doors to research and progress in biology, medicine, and health care. At the same time, these developments have produced a diversity of new issues to be addressed.

The National Academies of Sciences, Engineering, and Medicine has convened a Roundtable on Genomics and Precision Health (previously the Roundtable on Translating Genomic-Based Research for Health) that brings together leaders from academia, industry, government, foundations and associations, and representatives of patient and consumer interests who have a mutual concern and interest in addressing the issues surrounding the translation of genome-based research for use in maintaining and improving health. The mission of the Roundtable is to advance the field of genomics and improve the translation of research findings to health care, education, and policy. The Roundtable will discuss the translation process, identify challenges at various points in the process, and discuss approaches to address those challenges.

The field of genomics and its translation involves many disciplines, and takes place within different economic, social, and cultural contexts, necessitating a need for increased communication and understanding across these fields. As a convening mechanism for interested parties from diverse perspectives to meet and discuss complex issues of mutual concern in a neutral setting, the Roundtable: fosters dialogue across sectors and institutions; illuminates issues, but does not necessarily resolve them; and fosters collaboration among interested parties.

To achieve its objectives, the Roundtable conducts structured discussions, workshops, and symposia. Workshop summaries will be published and collaborative efforts among members are encouraged (e.g., journal articles). Specific issues

and agenda topics are determined by the Roundtable membership, and span a broad range of issues relevant to the translation process.

Issues may include the integration and coordination of genomic information into health care and public health including encompassing standards for genetic screening and testing, improving information technology for use in clinical decision making, ensuring access while protecting privacy, and using genomic information to reduce health disparities. The patient and family perspective on the use of genomic information for translation includes social and behavioral issues for target populations. There are evolving requirements for the health professional community, and the need to be able to understand and responsibly apply genomics to medicine and public health.

Of increasing importance is the need to identify the economic implications of using genome-based research for health. Such issues include incentives, cost-effectiveness, and sustainability.

Issues related to the developing science base are also important in the translation process. Such issues could include studies of gene-environment interactions, as well as the implications of genomics for complex disorders such as addiction, mental illness, and chronic diseases.

Roundtable sponsors include federal agencies, pharmaceutical companies, medical and scientific associations, foundations, and patient/public representatives. For more information about the Roundtable on Genomics and Precision Health, please visit our website at nationalacademies.org/GenomicsRT or contact Sarah Beachy at 202-334-2217, or by e-mail at sbeachy@nas.edu.

Roundtable on Genomics and Precision Health Membership

Robert Nussbaum, M.D. (Co-chair) UCSF Medical Center
Catherine A. Wicklund, M.S., CGC (Co-chair) National Society of Genetic Counselors

Devin Absher, Ph.D.

Kaiser Foundation Health Plan, Inc.

Charles Lee, Ph.D., FACMG

The Jackson Laboratory for Genomic Medicine (JAX)

James Beck, Ph.D.

Parkinson's Foundation

Debra Leonard, M.D., Ph.D.

The University of Vermont Medical Center

Natasha Bonhomme

Expecting Health

Christa Lese Martin, Ph.D., FACMG

Geisinger

Christina Daulton, M.A.

National Human Genome Research Institute

Jamie Lopes, Ph.D., FACMG

Illumina, Inc.

Aaron Goldenberg, Ph.D.

Association of Public Health Laboratories

Toby Lowe

U.S. Food and Drug Administration

Jennifer Goldsack, M.Chem, M.A., M.B.A.

Digital Medicine Society (DiMe)

Jennifer Moser, Ph.D.

U.S. Department of Veterans Affairs

Richard Hodes, M.D.

National Institute on Aging

Kenneth Offit, M.D., MPH

American Society of Clinical Oncology

Mira Irons, M.D.

American College of Medical Genetics and Genomics

Amanda Perl

American Society of Human Genetics

Jennie Jarrett, PharmD, MMedEd, PhD

American Medical Association

Jonathan Pevsner, Ph.D.

National Institute of Mental Health

Katherine Johansen Taber, Ph.D.

Myriad Women's Health

Kathryn A. Phillips, Ph.D.

University of California, San Francisco

Sarah Kalia, Ph.D., S.M., Sc.M., CGC

National Cancer Institute

Victoria M. Pratt, Ph.D., FACMG

Association for Molecular Pathology

Alisha Keehn, M.P.A.

Health Resources and Services Administration

Sheri Schully, Ph.D.

All of Us Research Program, NIH

Muin Khoury, M.D., Ph.D.

Emory University

Anil Shanker, Ph.D.

Meharry Medical College

Bruce Korf, M.D., Ph.D.

Global Genomic Medicine Collaborative (G2MC)

**Angela Starkweather, Ph.D., ACNP-BC, FAANP,
FAAN**

American Academy of Nursing

The National Academy of Sciences, National Academy of Engineering, and National Academy of Medicine work together as the National Academies of Sciences, Engineering, and Medicine ("the Academies") to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The Academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine.

Jacquelyn Taylor, Ph.D.
Columbia University School of Nursing

Sharon Terry, M.A.
Genetic Alliance

Joyce Tung, Ph.D.
23andMe

Karen Weck, M.D.
College of American Pathologists

Sarah Wordsworth, Ph.D.
University of Oxford

Project Staff

Sarah H. Beachy, Ph.D., PMP, *Roundtable Director*
Ashley Pitt, *Senior Program Assistant*

The National Academy of Sciences, National Academy of Engineering, and National Academy of Medicine work together as the National Academies of Sciences, Engineering, and Medicine (“the Academies”) to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The Academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine.